CAS 90779-69-4: Atosiban
Formula:C43H67N11O12S2
InChI:InChI=1/C43H67N11O12S2/c1-5-23(3)35-41(63)53-36(24(4)55)42(64)50-29(20-32(45)56)38(60)51-30(43(65)54-17-8-10-31(54)40(62)49-27(9-7-16-44)37(59)47-21-33(46)57)22-68-67-18-15-34(58)48-28(39(61)52-35)19-25-11-13-26(14-12-25)66-6-2/h11-14,23-24,27-31,35-36,55H,5-10,15-22,44H2,1-4H3,(H2,45,56)(H2,46,57)(H,47,59)(H,48,58)(H,49,62)(H,50,64)(H,51,60)(H,52,61)(H,53,63)/t23-,24+,27-,28+,29-,30-,31-,35-,36?/m0/s1
Synonyms:- Atosiban [USAN:INN]
- Rwj 22164
- 1-(3-Mercaptopropionic acid)-2-(3-(p-ethoxyphenyl)-D-alanine)-4-L-threonine-8-L-ornithineoxytocin
- 1-Deamino-2D-tyr-(OEt)-4-thr-8-orn-oxytocin
- Atosibanum
- Atosibanum [INN-Latin]
- Orf 22164
- Tractocile
- Unii-081D12Si0Z
- Oxytocin, 1-(3-mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithine-
- 1-({(4R,7S,13S,16R)-7-(2-amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-16-(4-ethoxybenzyl)-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-ornithylglycinamide
Sort by
Found 6 products.
Atosiban Acetate
CAS:Formula:C43H67N11O12S2Purity:95%~99%Color and Shape:White to Off-white PowderMolecular weight:994.189Atosiban
CAS:Oxytocin/vasopressin receptor antagonist.Formula:C43H67N11O12S2Purity:99.4%Color and Shape:WhiteMolecular weight:994.2Atosiban
CAS:Formula:C43H67N11O12S2Purity:≥ 98%Color and Shape:White to off-white powderMolecular weight:994.19Atosiban
CAS:Atosiban (RW22164), an oxytocin/vasopressin inhibitor, halts premature labor as an intravenous tocolytic, reducing uterine contractions rapidly.Formula:C43H67N11O12S2Purity:98%Color and Shape:SolidMolecular weight:994.19Atosiban
CAS:Atosiban is a drug used to prevent preterm birth in pregnant women. The drug binds to and blocks the action of oxytocin, a hormone that stimulates uterine contractions, preventing preterm birth. Atosiban prevents uterine contractions by binding to oxytocin receptors and blocking them from binding with oxytocin. Atosiban also has anti-inflammatory properties and can be used as an analgesic. Atosiban is administered orally as a prodrug that is converted into the active form in the intestines. This conversion is dependent on the presence of an intestinal disulfide bond reductase enzyme, which converts atosiban to its active form by reducing the disulfide bond between two cysteine residues found within the molecule. Atosiban has been shown to have few side effects in women, but may cause nausea or vomiting after administration.Formula:C43H67N11O12S2Purity:Min. 95%Molecular weight:994.2 g/molAtosiban
CAS:AtosibanPurity:99.2% by hplc (Typical Value in Batch COA)Color and Shape: sterile filtered white lyophilized (freeze-dried) powder.Molecular weight:994.19g/mol
